Raul D Santos Selected Research

Chylomicrons

9/2021	Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion.
3/2014	Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects.
3/2012	The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: study with artificial emulsions.
10/2004	Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease.
6/2004	Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study.
2/2004	Clearance of a 3H-labeled chylomicron-like emulsion following the acute phase of myocardial infarction.
2/2003	Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins.
4/2002	LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raul D Santos Research Topics

Disease

71	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 08/2006
64	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 02/2024 - 07/2005
53	Atherosclerosis 03/2024 - 08/2006
28	Coronary Artery Disease (Coronary Atherosclerosis) 03/2024 - 04/2002
27	Dyslipidemias (Dyslipidemia) 02/2024 - 02/2003
27	Inflammation (Inflammations) 10/2023 - 05/2007
25	Hypertension (High Blood Pressure) 01/2024 - 06/2003
23	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 01/2007
22	Coronary Disease (Coronary Heart Disease) 09/2019 - 01/2005
17	Obesity 01/2023 - 03/2006
16	Hypercholesterolemia 01/2024 - 01/2013
14	Homozygous Familial Hypercholesterolemia 03/2024 - 04/2008
14	Myocardial Infarction 03/2024 - 02/2004
13	Type 2 Diabetes Mellitus (MODY) 05/2023 - 05/2009
13	Inborn Genetic Diseases (Disease, Hereditary) 08/2022 - 03/2010
9	Xanthomatosis (Xanthoma) 01/2017 - 02/2008
8	Insulin Resistance 05/2023 - 04/2005
8	Hypertriglyceridemia 04/2023 - 03/2006
7	COVID-19 01/2024 - 01/2021
7	Stroke (Strokes) 07/2023 - 05/2009
7	Non-alcoholic Fatty Liver Disease 11/2022 - 01/2014
4	Heart Failure 02/2024 - 05/2007
4	Chronic Renal Insufficiency 02/2024 - 06/2020
4	Diabetes Mellitus 01/2024 - 01/2018
4	Injection Site Reaction 01/2019 - 03/2010
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017 - 01/2007
3	Hypothyroidism 10/2023 - 11/2020
3	Vascular Diseases (Vascular Disease) 01/2023 - 08/2016
3	Weight Loss (Weight Reduction) 07/2022 - 06/2011
3	Hyperthyroidism 05/2022 - 11/2020
3	Unstable Angina 01/2019 - 07/2016
3	Overweight 01/2018 - 07/2013
3	Hyperlipidemias (Hyperlipidemia) 01/2017 - 02/2003
3	Vascular Calcification 12/2008 - 05/2007
2	ST Elevation Myocardial Infarction 03/2024 - 09/2015
2	Ischemic Stroke 12/2022 - 07/2016
2	Body Weight (Weight, Body) 07/2022 - 01/2022
2	Morbid Obesity 01/2022 - 01/2021
2	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 09/2021 - 09/2018
2	Costello Syndrome 09/2021 - 09/2018

Drug/Important Bio-Agent (IBA)

66	LDL CholesterolIBA 03/2024 - 04/2002
65	oxidized low density lipoproteinIBA 03/2024 - 04/2002
64	LipidsIBA 03/2024 - 03/2003
45	CholesterolIBA 03/2024 - 03/2003
41	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2024 - 05/2007
33	Triglycerides (Triacylglycerol)IBA 04/2023 - 02/2003
30	HDL CholesterolIBA 11/2022 - 02/2004
24	Lipoproteins (Lipoprotein)IBA 01/2024 - 02/2003
21	C-Reactive ProteinIBA 10/2023 - 09/2009
18	CalciumIBA 01/2023 - 01/2005
16	Glucose (Dextrose)FDA LinkGeneric 05/2023 - 10/2005
16	LDL Lipoproteins (beta Lipoproteins)IBA 12/2022 - 09/2007
14	Biomarkers (Surrogate Marker)IBA 10/2023 - 09/2008
13	Lipoprotein(a)IBA 12/2023 - 08/2012
10	Proprotein Convertase 9IBA 03/2024 - 08/2012
10	HDL LipoproteinsIBA 03/2024 - 04/2005
9	LDL Receptors (LDL Receptor)IBA 11/2021 - 07/2005
9	EmulsionsIBA 03/2014 - 04/2002
8	evolocumabIBA 03/2024 - 01/2017
8	PCSK9 InhibitorsIBA 11/2022 - 01/2016
8	ChylomicronsIBA 09/2021 - 04/2002
8	ApolipoproteinsIBA 01/2021 - 04/2002
8	mipomersenIBA 11/2019 - 03/2010
7	Monoclonal AntibodiesIBA 03/2024 - 01/2016
7	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2020 - 02/2004
7	Uric Acid (Urate)IBA 12/2012 - 04/2005
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2008
5	alirocumabIBA 02/2024 - 01/2016
5	Blood Glucose (Blood Sugar)IBA 01/2022 - 05/2006
5	BMS201038IBA 03/2021 - 08/2014
5	bococizumabIBA 07/2018 - 08/2016
5	Adenosine Triphosphate (ATP)IBA 01/2014 - 08/2008
3	Antihypertensive Agents (Antihypertensives)IBA 02/2024 - 01/2018
3	Atorvastatin (Lipitor)FDA Link 01/2024 - 02/2003
3	ALN-PCSIBA 01/2024 - 01/2021
3	Small Interfering RNA (siRNA)IBA 01/2024 - 01/2021
3	omega-Chloroacetophenone (Mace)IBA 12/2022 - 07/2016
3	Antisense OligonucleotidesIBA 01/2021 - 09/2014
3	EnzymesIBA 01/2021 - 10/2005
3	Apolipoproteins B (ApoB)IBA 01/2021 - 04/2002
3	Ezetimibe (Zetia)FDA Link 09/2019 - 03/2014
3	Simvastatin (Zocor)FDA LinkGeneric 03/2014 - 07/2005
2	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 03/2024 - 09/2015
2	Phospholipids (Phosphatides)FDA LinkGeneric 03/2024 - 09/2015
2	Phosphatidic Acids (Phosphatidic Acid)IBA 03/2024 - 09/2015
2	Glycoproteins (Glycoprotein)IBA 10/2023 - 10/2023
2	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2023 - 07/2022
2	MicroRNAs (MicroRNA)IBA 04/2023 - 01/2023
2	Interleukin-6 (Interleukin 6)IBA 12/2022 - 09/2015
2	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 11/2022 - 10/2021
2	Apolipoprotein C-IIIIBA 11/2022 - 01/2020
2	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 10/2021 - 03/2021
2	Amino Acids FDA Link 04/2021 - 08/2010
2	evinacumabIBA 03/2021 - 01/2021
2	fibrin fragment D (D-dimer)IBA 01/2021 - 06/2013

Therapy/Procedure

41	Therapeutics 03/2024 - 06/2004
6	Secondary Prevention 01/2024 - 06/2004
4	Bariatric Surgery 11/2023 - 01/2021
3	Renal Dialysis (Hemodialysis) 09/2013 - 01/2008
2	Mediterranean Diet 01/2021 - 12/2019